{"id":72487,"date":"2026-08-14T11:49:51","date_gmt":"2026-08-14T03:49:51","guid":{"rendered":"https:\/\/flcube.com\/?p=72487"},"modified":"2026-08-14T11:49:52","modified_gmt":"2026-08-14T03:49:52","slug":"iaso-biotherapeutics-completes-acquisition-of-medisix-therapeutics-adding-pebl-based-car-t-cell-therapy-platform-for-t-cell-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72487","title":{"rendered":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>IASO Biotherapeutics<\/strong>, a Chinese cell therapy innovator, announced today that it has <strong>completed its acquisition<\/strong> of <strong>MediSix Therapeutics<\/strong>, a <strong>Singapore\u2011based immune cell engineering and cell therapy company<\/strong>. The transaction brings MediSix&#8217;s proprietary <strong>PEBL (Protein Expression Blocker) platform<\/strong> and lead program <strong>IASO107<\/strong> into IASO&#8217;s portfolio, strengthening its <strong>CAR\u2011T cell therapy<\/strong> pipeline for hard\u2011to\u2011treat <strong>T\u2011cell malignancies<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-snapshot\" class=\"wp-block-heading\">Deal Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>IASO Biotherapeutics (China, cell therapy innovator)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>MediSix Therapeutics (Singapore)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>Transaction Status<\/strong><\/td><td>Completed<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Acquire PEBL platform technology and IASO107 lead asset for T\u2011cell malignancy CAR\u2011T cell therapy<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Not disclosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-target-profile-medisix-therapeutics\" class=\"wp-block-heading\">Target Profile \u2013 MediSix Therapeutics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2016, headquartered in Singapore<\/li>\n\n\n\n<li><strong>Founder:<\/strong> Professor <strong>Dario Campana<\/strong>, an internationally renowned expert in <strong>translational immunology<\/strong><\/li>\n\n\n\n<li><strong>Core Focus:<\/strong> Addressing critical challenges in cell therapy for <strong>T\u2011cell malignancies<\/strong><\/li>\n\n\n\n<li><strong>Lead Asset:<\/strong> <strong>IASO107<\/strong> (formerly <strong>PCART7<\/strong>), currently in clinical evaluation with leading international research hospitals<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-technology-platform-pebl-protein-expression-blocker\" class=\"wp-block-heading\">Technology Platform \u2013 PEBL (Protein Expression Blocker)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Specifically blocks the expression of target proteins on the cell surface of <strong>CAR\u2011T cells<\/strong>, effectively reducing <strong>fratricide<\/strong> \u2014 the self\u2011destruction of therapeutic T cells that share antigens with target cancer cells.<\/li>\n\n\n\n<li><strong>Key Advantage:<\/strong> Enables targeting of <strong>shared antigens between T cells and target cells<\/strong>, a long\u2011standing bottleneck in treating T\u2011cell malignancies.<\/li>\n\n\n\n<li><strong>Research Integration:<\/strong> Combines <strong>in vitro and in vivo CAR\u2011T research<\/strong>, establishing exclusive technological barriers and competitive advantages across both <strong>hematologic malignancies and solid tumors<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-progress-iaso107\" class=\"wp-block-heading\">Clinical Progress \u2013 IASO107<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Status:<\/strong> Ongoing clinical evaluation in collaboration with <strong>leading international research hospitals<\/strong><\/li>\n\n\n\n<li><strong>Early Readout:<\/strong> Encouraging signs of both <strong>efficacy and safety<\/strong> reported<\/li>\n\n\n\n<li><strong>Prior Designation:<\/strong> Formerly known as <strong>PCART7<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiated Asset:<\/strong> The PEBL platform addresses one of the toughest problems in <strong>CAR\u2011T cell therapy<\/strong> \u2014 T\u2011cell malignancies, where conventional CAR\u2011T approaches fail due to fratricide.<\/li>\n\n\n\n<li><strong>Pipeline Depth:<\/strong> The acquisition adds a clinically evaluated lead candidate (<strong>IASO107<\/strong>) rather than a preclinical asset, shortening IASO&#8217;s path to data readouts.<\/li>\n\n\n\n<li><strong>Global Reach:<\/strong> MediSix&#8217;s international clinical collaborations extend IASO Biotherapeutics&#8217; footprint beyond China into global research networks.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Combining IASO&#8217;s cell therapy development capabilities with MediSix&#8217;s proprietary engineering platform creates a differentiated player in hematologic malignancies and solid tumors.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the integration of MediSix Therapeutics, clinical development of IASO107, and potential applications of the PEBL platform. Actual results may differ due to risks including clinical outcomes, regulatory requirements, and competitive dynamics in cell therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72489,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[77,594,4897],"class_list":["post-72487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-iaso-biotherapeutics","tag-medisix-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix&#039;s proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO&#039;s portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies\" \/>\n<meta property=\"og:description\" content=\"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix&#039;s proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO&#039;s portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-14T03:49:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-14T03:49:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies\",\"datePublished\":\"2026-08-14T03:49:51+00:00\",\"dateModified\":\"2026-08-14T03:49:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1401.webp\",\"keywords\":[\"Cell-therapy\",\"IASO Biotherapeutics\",\"MediSix Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72487#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72487\",\"name\":\"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1401.webp\",\"datePublished\":\"2026-08-14T03:49:51+00:00\",\"dateModified\":\"2026-08-14T03:49:52+00:00\",\"description\":\"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix's proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO's portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72487\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1401.webp\",\"width\":1080,\"height\":608,\"caption\":\"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry","description":"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix's proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO's portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72487","og_locale":"en_US","og_type":"article","og_title":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies","og_description":"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix's proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO's portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.","og_url":"https:\/\/flcube.com\/?p=72487","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-14T03:49:51+00:00","article_modified_time":"2026-08-14T03:49:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies","datePublished":"2026-08-14T03:49:51+00:00","dateModified":"2026-08-14T03:49:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72487"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","keywords":["Cell-therapy","IASO Biotherapeutics","MediSix Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72487#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72487","url":"https:\/\/flcube.com\/?p=72487","name":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72487#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72487#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","datePublished":"2026-08-14T03:49:51+00:00","dateModified":"2026-08-14T03:49:52+00:00","description":"IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition of MediSix Therapeutics, a Singapore\u2011based immune cell engineering and cell therapy company. The transaction brings MediSix's proprietary PEBL (Protein Expression Blocker) platform and lead program IASO107 into IASO's portfolio, strengthening its CAR\u2011T cell therapy pipeline for hard\u2011to\u2011treat T\u2011cell malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72487"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72487#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","width":1080,"height":608,"caption":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics \u2013 Adding PEBL\u2011Based CAR\u2011T Cell Therapy Platform for T\u2011Cell Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1401.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72487"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72487\/revisions"}],"predecessor-version":[{"id":72490,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72487\/revisions\/72490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72489"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}